Avenue Therapeutics Inc (ATXI)

$0.1355

-0.01

(-4.04%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Avenue Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 135.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 253.0% return, outperforming this stock by 352.8%

Performance

  • $0.14
    $0.14
    $0.14
    downward going graph

    3.36%

    Downside

    Day's Volatility :6.43%

    Upside

    3.18%

    downward going graph
  • $0.11
    $1.28
    $0.14
    downward going graph

    19.64%

    Downside

    52 Weeks Volatility :91.21%

    Upside

    89.06%

    downward going graph

Returns

PeriodAvenue Therapeutics IncIndex (Russel 2000)
3 Months
-12.47%
0.0%
6 Months
-77.61%
0.0%
1 Year
-87.57%
-0.7%
3 Years
-99.81%
-21.3%

Highlights

Market Capitalization
6.6M
Book Value
$0.06
Earnings Per Share (EPS)
-0.98
PEG Ratio
0.0
Wall Street Target Price
0.75
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-209.03%
Return On Equity TTM
-535.1%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.98
Quarterly Earnings Growth YOY
-0.76
EPS Estimate Current Year
-0.41
EPS Estimate Next Year
-0.37
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Avenue Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 453.51%

Current $0.14
Target $0.75

Technicals Summary

Sell

Neutral

Buy

Avenue Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avenue Therapeutics Inc
Avenue Therapeutics Inc
-12.58%
-77.61%
-87.57%
-99.81%
-99.8%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avenue Therapeutics Inc
Avenue Therapeutics Inc
NA
NA
0.0
-0.41
-5.35
-2.09
NA
0.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avenue Therapeutics Inc
Avenue Therapeutics Inc
Buy
$6.6M
-99.8%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Geode Capital Management, LLC

    0.14%
  • Vanguard Group Inc

    0.12%
  • State Street Corporation

    0.08%
  • Millennium Management LLC

    0.08%
  • TWO SIGMA SECURITIES, LLC

    0.07%
  • HRT FINANCIAL LLC

    0.07%

Company Information

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Organization
Avenue Therapeutics Inc
Employees
3
CEO
Dr. Alexandra MacLean M.D.
Industry
Health Technology

FAQs